Saudi Arabia Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Related Markets
Saudi Arabia recombinant protein therapeutics cdmo market highlights
- The Saudi Arabia recombinant protein therapeutics cdmo market generated a revenue of USD 177.8 million in 2023 and is expected to reach USD 401.5 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 12.3% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 177.8 million |
| Market revenue in 2030 | USD 401.5 million |
| Growth rate | 12.3% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.9% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 312.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.48% in 2023. Horizon Databook has segmented the Saudi Arabia recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia’s business environment is anticipated to witness a notable increase in investments from the biopharmaceutical sector due to the rising demand for healthcare services and a surge in fundraising activities within the industry. In recent years, pharmaceutical companies have demonstrated a growing interest in investing in the country.
This attraction is fueled by the country’s sizable & expanding population, robust healthcare infrastructure, and the government’s committed initiatives to advance the sector in alignment with its Vision 2030 plan. Moreover, Saudi Arabia’s FDA has created a state-of-the-art regulatory framework that supports advanced clinical trials and the development & manufacturing of drugs in the country.
Furthermore, the availability of world-class healthcare infrastructure, the increasing number of industry experts trained in Western medicine, a rapid rise in investments in the contract manufacturing industry, and the growing government initiatives are some of the factors expected to boost market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Enzene Biosciences | View profile | 251-500 | Pune, Maharashtra, India, Asia | http://www.enzene.com/ |
| Biovian | View profile | 101-250 | Turku, Western Finland, Finland, Europe | http://www.biovian.com |
| HALIX | View profile | 11-50 | Leiden, Zuid-Holland, The Netherlands, Europe | https://www.halix.nl |
| Richter-Helm | View profile | 251-500 | Hamburg, Hamburg, Germany, Europe | http://www.richter-helm.eu |
| Batavia Biosciences | View profile | 101-250 | Leiden, Zuid-Holland, The Netherlands, Europe | http://www.bataviabiosciences.com/ |
| Curia | View profile | 1001-5000 | Albany, New York, United States, North America | https://curiaglobal.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Saudi Arabia recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Saudi Arabia Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
